Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

SELL
$98.98 - $115.74 $4.95 Million - $5.79 Million
-50,000 Reduced 15.8%
266,400 $30.8 Million
Q2 2023

Aug 14, 2023

BUY
$96.34 - $112.38 $11.2 Million - $13.1 Million
116,400 Added 58.2%
316,400 $32.5 Million
Q1 2023

May 15, 2023

BUY
$107.32 - $113.5 $3.11 Million - $3.29 Million
29,000 Added 16.96%
200,000 $21.8 Million
Q4 2022

Feb 14, 2023

BUY
$62.39 - $113.8 $10.7 Million - $19.5 Million
171,000 New
171,000 $19.5 Million
Q2 2022

Aug 15, 2022

SELL
$79.4 - $116.36 $6.99 Million - $10.2 Million
-88,000 Reduced 4.01%
2,108,555 $168 Million
Q1 2022

May 16, 2022

SELL
$86.42 - $109.81 $26.2 Million - $33.3 Million
-303,500 Reduced 12.14%
2,196,555 $231 Million
Q4 2021

Feb 14, 2022

SELL
$98.56 - $119.91 $10.9 Million - $13.2 Million
-110,300 Reduced 4.23%
2,500,055 $269 Million
Q3 2021

Nov 15, 2021

SELL
$91.91 - $110.37 $28.7 Million - $34.4 Million
-311,800 Reduced 10.67%
2,610,355 $286 Million
Q2 2021

Aug 16, 2021

SELL
$86.24 - $95.92 $19.2 Million - $21.3 Million
-222,200 Reduced 7.07%
2,922,155 $274 Million
Q1 2021

May 17, 2021

BUY
$71.83 - $95.48 $9.74 Million - $12.9 Million
135,600 Added 4.51%
3,144,355 $289 Million
Q3 2020

Nov 16, 2020

BUY
$55.23 - $79.93 $7.78 Million - $11.3 Million
140,845 Added 4.91%
3,008,755 $234 Million
Q2 2020

Aug 14, 2020

BUY
$30.2 - $56.98 $15.9 Million - $30 Million
526,210 Added 22.47%
2,867,910 $159 Million
Q1 2020

May 15, 2020

BUY
$24.87 - $38.56 $18.9 Million - $29.3 Million
759,400 Added 47.99%
2,341,700 $69.4 Million
Q4 2019

Feb 14, 2020

BUY
$25.43 - $36.67 $40.2 Million - $58 Million
1,582,300 New
1,582,300 $57.3 Million

Others Institutions Holding HZNP

About Horizon Therapeutics Public Ltd Co


  • Ticker HZNP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 230,384,000
  • Description
  • Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...
More about HZNP
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.